A phase III trial of remetinostat for the treatment of cutaneous T-cell lymphoma

Trial Profile

A phase III trial of remetinostat for the treatment of cutaneous T-cell lymphoma

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2017 According to a Medivir AB media release, based on the data from Phase II trial (see profile 243325) company is planning to initiate discussions with regulatory authorities with the aim of initiating this trial later in 2017.
    • 14 Nov 2016 New trial record
    • 02 Nov 2016 According to a Medivir AB media release, the company plans to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top